Celularity INC 8-K filings

Celularity Inc. announced the immediate termination of its Chief Commercial Officer, Rick Gonzalez, effective August 5, 2026.

Celularity Inc. has entered into a $1 million loan agreement with a trust affiliated with a major shareholder and announced the resignation of a board member.

Celularity Inc. has appointed Steven N. Gordon as Chief Operating and Administrative Officer and Director, and K. Harold Fletcher as Chief Legal and Strategy Officer.

Celularity Inc. has been notified by Nasdaq that its market value of listed securities has fallen below the required $35 million threshold.

Celularity Inc. announced the appointment of Rick Gonzalez as Chief Commercial Officer to drive commercialization of its placental-derived cell therapies, including cenplacel-L and its Lifebank platform, supporting its strategic focus on longevity and regenerative medicine.

Celularity Inc. has entered into a settlement agreement with Helena Global Investment Opportunities 1 Ltd. to resolve outstanding claims and restructure existing debt obligations.

Celularity Inc. announced an amendment to its asset purchase and license agreement with NexGel, Inc., receiving $13.3 million and potential future milestones, while also addressing a default notice from Helena regarding a convertible note.

Celularity Inc. announced the departure of its Acting Chief Financial Officer, Joseph DosSantos, and the immediate appointment of John Sprague to the role.

Celularity Inc. has amended the employment agreement for Senior Executive Vice President John Haines, extending severance benefits and accelerating equity vesting upon termination.

Celularity Inc. has closed a $10 million financing round, including senior secured and convertible notes, with potential for an additional $2 million, aimed at bolstering its financial position and strategic shift towards healthy aging and performance optimization.

Celularity Inc. announced the results of its Annual Meeting, where stockholders elected Class I Directors, ratified its accounting firm, but rejected an amendment to increase shares for its equity incentive plan.

Celularity Inc. received a warning letter from the U.S. Food and Drug Administration regarding marketing materials for its Interfyl product.

Celularity Inc. has entered into a private placement agreement to raise up to $6.67 million through the issuance of Series A Convertible Preferred Stock and warrants, with an initial $2 million tranche closing immediately.

Celularity Inc. announced that Nasdaq has confirmed its compliance with Listing Rule 5250(c)(1), closing the previous matter.

Celularity Inc. announced a significant balance sheet restructuring, retiring $41.6 million in senior secured debt through the sale and subsequent exclusive licensing of its intellectual property assets.

Celularity Inc. acquired preferred stock in Defeye, Inc. for $2.89 million in product credits while simultaneously facing a Nasdaq delisting notice for failing to file its quarterly reports.

Celularity Inc. announced it issued a $6.8 million promissory note and warrants to purchase 3.7 million shares of Class A common stock to an investor, with proceeds partially used to repay an existing loan.

Celularity Inc. has entered into a private placement agreement with an institutional investor to raise $2 million through the sale of Class A common stock and accompanying warrants.

Celularity Inc. has amended forbearance agreements with C. V. Starr & Co., Inc. and Resorts World Inc Pte Ltd, repricing existing warrants to lower exercise prices and issuing new warrants, signaling ongoing financial restructuring.

Celularity Inc. announced a private placement of Class A common stock and a significant adjustment to existing warrants, aiming to raise $1.035 million for working capital and general corporate purposes.

Celularity Inc. announced the termination of its Chief Financial Officer, David Beers, without cause, and the appointment of Joseph DosSantos as interim CFO, while also retaining CFO Squad for financial and reporting support.

Celularity Inc. announced the appointment of Vincent LeVien as a Class II director, effective June 5, 2025, also assigning him to the Audit and Nominating and Corporate Governance Committees.

Celularity Inc. extends the maturity date of its convertible promissory note with YA II PN, Ltd. in exchange for issuing restricted common stock.

Dean Kehler resigned from Celularity Inc.'s Board of Directors on May 14, 2025, with no reported disagreements with the company.

Celularity reports a significant increase in net revenues for 2024, driven by strong product sales and reduced operating expenses.

Celularity Inc. has been notified by Nasdaq that it has regained compliance with Listing Rule 5250(f) after paying its past due fee balance of $70,000.

Celularity Inc. received a formal notice from Nasdaq regarding non-compliance with listing requirements due to the delayed filing of its 2024 Form 10-K.

Celularity Inc. extends the maturity date of its convertible note with YA II PN, Ltd. (Yorkville) to May 12, 2025, issuing 100,000 shares of Class A common stock in exchange for forbearance and extending the maturity date.

Celularity Inc. announces a Master Services Collaboration Agreement with BlueSphere Bio, Inc. for manufacturing activities related to BSB's cell therapy products.

Celularity Inc. has entered into binding term sheets with Resorts World Inc Pte Ltd (RWI) and C.V. Starr & Co., Inc. (Starr) to extend forbearance agreements and loan maturities, contingent on a future public offering.